Suzhou Basecare Medical Corporation Limited provided unaudited operating statistics guidance for the Group for the six months ended June 30, 2024. For the period, the company expects total revenue to be within the range of RMB 127.3 million to RMB 138.4 million. The increase in revenue was primarily attributable to the following reasons: The Group acquired BMX Holdco Pte.

Ltd. and incorporated its financial results into global sales results. The Group has established an extensive global sales network, and have achieved international sales of domestic self-developed products while maintaining growth in overseas results. In the first half of the year, the company achieved significant growth in the sales of equipment such as embryo incubators and products such as embryo culture solution to customers in Spain, the United Kingdom and the United States, and successfully developed numerous group customers.

The company expected to deliver products to several new customers in the second half of the year; and business in China maintained steady growth. Under the incentive policies of several provinces and cities in China to include some assisted reproductive projects in the scope of medical insurance, the sales of the Company's core products in the five major scenarios have maintained steady growth. The sales of PGT kits, embryo incubators and ultra-low temperature storage products have all achieved the expected growth rate.

provided software and other ancillary support to customers while selling testing kits, equipment and consumables. It is expected that sales in China will continue to grow with the constant introduction of incentive policies to the assisted reproduction industry.